Guardant Health (GH) Set to Announce Earnings on Thursday

Guardant Health (NASDAQ:GH - Get Free Report) will announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter. Guardant Health has set its FY 2024 guidance at EPS.Investors that wish to listen to the company's conference call can do so using this link.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.65). The business had revenue of $155.05 million during the quarter, compared to the consensus estimate of $151.71 million. Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Stock Performance

GH traded up $0.32 on Thursday, hitting $18.58. The company's stock had a trading volume of 954,660 shares, compared to its average volume of 1,849,123. The company's 50 day simple moving average is $18.47 and its 200-day simple moving average is $22.65. The firm has a market cap of $2.26 billion, a P/E ratio of -4.27 and a beta of 0.92. Guardant Health has a 12 month low of $15.81 and a 12 month high of $41.06. The company has a quick ratio of 6.24, a current ratio of 6.54 and a debt-to-equity ratio of 7.18.

Insider Buying and Selling

In other news, insider Kumud Kalia bought 2,187 shares of the firm's stock in a transaction on Monday, March 18th. The stock was acquired at an average cost of $17.82 per share, with a total value of $38,972.34. Following the completion of the acquisition, the insider now owns 12,722 shares of the company's stock, valued at $226,706.04. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on GH shares. JPMorgan Chase & Co. lowered their price objective on shares of Guardant Health from $60.00 to $45.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. The Goldman Sachs Group lowered their price objective on shares of Guardant Health from $32.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, April 15th. Piper Sandler lowered their price objective on shares of Guardant Health from $40.00 to $30.00 and set an "overweight" rating on the stock in a research report on Monday, February 26th. Craig Hallum initiated coverage on shares of Guardant Health in a research report on Wednesday, April 24th. They issued a "buy" rating and a $28.00 target price on the stock. Finally, Canaccord Genuity Group decreased their target price on shares of Guardant Health from $45.00 to $30.00 and set a "buy" rating on the stock in a research report on Monday. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.91.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.